Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib.
Despoina PantaziNikoleta NtemouAlexios BrentasDimitrios AlivertisKonstantinos SkobridisAlexandros D TselepisPublished in: Drug design, development and therapy (2019)
Our results show that there is considerable potential to develop synthetic analogues of imatinib and nilotinib, as TKIs with antiplatelet properties and therefore being suitable to target cancer progression and metastasis, as well as CAT by inhibiting platelet activation.